Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160
Annals of Rheumatic Diseases,

Smolen JS et al. – In patients with active rheumatoid arthritis (RA) who discontinued previous TNF–antagonist treatment, golimumab 50 and 100 mg injections every 4 weeks yielded sustained improvements in signs/symptoms and physical function in 57–67% of patients who continued treatment. Golimumab safety was consistent with other anti–TNF agents, although definitive conclusions regarding long–term safety require further monitoring.

Methods
  • Results through week 24 of this multicentre, randomised, double–blind, placebo–controlled study of active RA (≥ 4 tender, ≥ 4 swollen joints) were previously reported.
  • Patients received placebo (Group 1), 50 mg golimumab (Group 2) or 100 mg golimumab (Group 3) subcutaneous injections every 4 weeks.
  • Patients from Groups 1 and 2 with <20% improvement in tender/swollen joints at week 16 early escaped to golimumab 50 mg and 100 mg, respectively.
  • At week 24, Group 1 patients crossed over to golimumab 50 mg, Group 2 continued golimumab 50/100 mg per escape status and Group 3 maintained dosing..
  • Data through week 160 are reported

Results
  • 459 of the 461 randomised patients were treated; 236/459 (51%) continued treatment through week 160.
  • From week 24 to week 100, ACR20 (≥ 20% improvement in American College of Rheumatology criteria) response and ≥ 0.25 unit HAQ (Health Assessment Questionnaire) improvement were sustained in 70–73% and 75–81% of responding patients, respectively.
  • Overall at week 160, 63%, 67% and 57% of patients achieved ACR20 response and 59%, 65% and 64% had HAQ improvement ≥ 0.25 unit in Groups 1, 2 and 3, respectively.
  • Adjusted for follow–up duration, adverse event incidences (95% CI) per 100 patient–years among patients treated with golimumab 50 mg and 100 mg were 4.70 (2.63 to 7.75) and 8.07 (6.02 to 10.58) for serious infection, 0.95 (0.20 to 2.77) and 2.04 (1.09 to 3.49) for malignancy and 0.00 (0.00 to 0.94) and 0.62 (0.17 to 1.59) for death, respectively.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Could ibuprofen be an anti-aging medicine? Buck Institute for Research on Aging News, December 22, 2014

2 Rituximab for the treatment of relapses in ANCA-associated vasculitis Arthritis & Rheumatism, August 1, 2014    Clinical Article

3 Mayo Clinic researchers: TNF inhibitors may increase cancer risk in the eye Mayo Clinic, November 19, 2014

4 Ten common mistakes in the management of lupus nephritis American Journal of Kidney Diseases, January 3, 2014    Clinical Article

5 Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: A meta-analysis Clinical Infectious Diseases, April 28, 2014    Evidence Based Medicine

6 Fish consumption and risk of rheumatoid arthritis: A dose-response meta-analysis Arthritis Research & Therapy, October 8, 2014    Evidence Based Medicine    Review Article

7 Identification of lymphoma predictors in patients with primary Sjögren's syndrome: A systematic literature review and meta-analysis Rheumatology International, June 5, 2014    Evidence Based Medicine    Review Article

8 Methotrexate and lung disease in rheumatoid arthritis – A meta-analysis of randomized controlled trials Arthritis & Rheumatism, December 27, 2013    Evidence Based Medicine    Review Article    Clinical Article

9 Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study Rheumatology, February 11, 2014    Clinical Article

10 The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: A systematic review and meta-analysis Lupus, November 26, 2014    Evidence Based Medicine    Review Article

11 Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: A multicentre, randomised, double-blind, non-inferiority trial versus celecoxib Annals of Rheumatic Diseases, January 23, 2015    Clinical Article

12 Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis Joint, Bone, Spine, July 3, 2014    Clinical Article

13 The comparative safety of TNF inhibitors in rheumatoid arthritis - a meta-analysis update of 44 randomized controlled trials American Journal of Medicine, October 6, 2014    Clinical Article

14 Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients Seminars in Arthritis and Rheumatism, January 5, 2015    Clinical Article

15 Intra articular injection with corticosteroids in patients with recent onset rheumatoid arthritis: subanalyses from the BeSt study Clinical Rheumatology, February 17, 2014    Clinical Article

16 A combination of celecoxib and famciclovir is efficacious in the treatment of fibromyalgia: Results of a phase IIa randomized, double-blind, placebo-controlled study American College of Rheumatology News, December 2, 2014    Clinical Article

17 Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis Seminars in Arthritis and Rheumatism, June 27, 2014    Evidence Based Medicine    Review Article

18 Coffee or tea consumption and the risk of rheumatoid arthritis: A meta-analysis Clinical Rheumatology, October 15, 2014    Clinical Article

19 Denosumab and osteonecrosis of the jaws: The pharmacology, pathogenesis and a report of two cases Australian Dental Journal, August 25, 2014

20 Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-analysis Annals of Rheumatic Diseases, January 7, 2015    Evidence Based Medicine    Review Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List